Oppenheimer Has Lowered Expectations for Perspective Therapeutics (NYSE:CATX) Stock Price

Perspective Therapeutics (NYSE:CATX) had its price target lowered by investment analysts at Oppenheimer from $22.00 to $16.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 417.80% from the stock’s current price.

Other analysts also recently issued reports about the company. Truist Financial started coverage on Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a report on Monday, September 9th. Royal Bank of Canada reduced their price target on shares of Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a report on Friday, August 16th. Wedbush reiterated an “outperform” rating and issued a $11.00 price target (down from $20.00) on shares of Perspective Therapeutics in a research report on Thursday. Finally, Bank of America assumed coverage on Perspective Therapeutics in a research report on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, Perspective Therapeutics presently has an average rating of “Buy” and a consensus target price of $19.43.

Perspective Therapeutics Stock Up 3.0 %

Shares of NYSE CATX opened at $3.09 on Friday. Perspective Therapeutics has a 52 week low of $2.28 and a 52 week high of $19.05. The company has a 50-day moving average of $11.75.

Perspective Therapeutics (NYSE:CATX) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21). The company had revenue of $0.37 million during the quarter. Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. As a group, research analysts anticipate that Perspective Therapeutics will post -0.86 EPS for the current fiscal year.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CATX. Vanguard Group Inc. lifted its stake in shares of Perspective Therapeutics by 34.6% during the first quarter. Vanguard Group Inc. now owns 17,780,106 shares of the company’s stock valued at $21,158,000 after buying an additional 4,566,356 shares during the period. Janus Henderson Group PLC acquired a new position in Perspective Therapeutics in the 1st quarter valued at $15,511,000. FMR LLC lifted its stake in shares of Perspective Therapeutics by 3,994.9% during the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after purchasing an additional 5,370,392 shares during the period. State Street Corp boosted its holdings in shares of Perspective Therapeutics by 119.6% during the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Finally, Nicholson Wealth Management Group LLC acquired a new stake in shares of Perspective Therapeutics during the third quarter worth $21,390,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.